The U.S. Drug Policy Landscape: Insights and Opportunities for Improving the View

Kilmer, Beau; Caulkins, Jonathan P.; Pacula, Rosalie Liccardo; Reuter, Peter

doi:10.7249/op393

Cited by 5 publications

(2 citation statements)

References 57 publications

(68 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table documents that the number of chronic cocaine users decreased by more than 20% from 2006 to 2010. At this point in the epidemic heavy cocaine users are becoming older and some are probably aging out ; however, it seems unlikely that such a large number would age out over such a short period of time. We are also unaware of research documenting that heavy cocaine users suddenly switched to other substances (e.g.…”

Section: Questions For Debatementioning

confidence: 99%

Cocaine's fall and marijuana's rise: questions and insights based on new estimates of consumption and expenditures in US drug markets

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Questions For Debatementioning

confidence: 99%

Cocaine's fall and marijuana's rise: questions and insights based on new estimates of consumption and expenditures in US drug markets

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…Some U.S. scholars note that drug policy research can manifest assumptions, deficiencies, and systemic biases that contribute to misinformation about drugs and people who use drugs (Brownstein, 2016; G. Hunt, Milhet, & Bergeron, 2011; Kilmer, Caulkins, Pacula, & Reuter, 2012; Kleinman, Caulkins, Hawken, & Kilmer, 2012; National Research Council, 2001; Netherland, 2016). In a recent example, in 2015, Nancy Campbell and David Herzberg hosted a U.S. symposium calling for the incorporation of gender analysis into critical drug scholarship (Campbell & Herzberg, 2017).…”

Section: Introductionmentioning

confidence: 99%

Developing a Transformative Drug Policy Research Agenda in the United States

Walker

Netherland

2018

Contemporary Drug Problems

View full text Add to dashboard Cite

Despite its strengths, drug policy scholarship in the United States has deficiencies and systemic biases that contribute to misinformation about drugs and people who use drugs. Factors ranging from funders' biases to an overemphasis on abstinence-only outcomes limit the scope and focus of drug policy research. These deficiencies and the highly politicized nature of drug policy reform have led U.S. decision-makers to largely reproduce the uninformed thinking that epitomizes failed drug policies. In an effort to address some of these limitations, we designed Unbounded Knowledge: Envisioning a New Future for Drug Policy Research, a project to engage researchers in thinking about how U.S. drug policy research should be transformed. The project involved a diverse group of multidisciplinary drug researchers and clinicians in a focused collaboration to identify what drug research should be-but is not-studying in the U.S. It consisted of: (1) a preliminary series of interviews with researchers, (2) identification of common research constraints and factors that would transform the direction of drug policy research in the U.S., and (3) a daylong workshop to craft an aspirational research agenda. Participants were broadly in consensus that significant changes are needed to create different ways to conduct drug policy research and new opportunities within the research environment. They also generated specific ideas for research that could better shape U.S. drug policies in ways that move beyond the dominant focus on criminalization and medicalization. This article offers recommendations generated by the project for improving drug policy research in the U.S.

show abstract